Abeona Therapeutics Inc. (ABEO) Financial Statements
Industry: Pharmaceutical Preparations
In fiscal 2025, Abeona Therapeutics reported revenue of $5.8M. Net income was $71.2M (a 1223.1% net margin), or $1.01 per diluted share. Gross margin was 73.7% and operating margin was -1536.9%. Operating activities generated -$76.3M of cash, leaving -$84.3M of free cash flow. At fiscal year end, Abeona Therapeutics held $219.6M in total assets against $60.4M in total liabilities, including $78.4M of cash and equivalents.
Open the full interactive Abeona Therapeutics financials → Quarterly statements, key ratios, valuation history and price charts.
Abeona Therapeutics Key Stats
| Share Price | $4.52 |
|---|---|
| Market Cap | $257.9M |
| P/E Ratio | 4.5 |
| 52-Week Range | $4.17 – $7.46 |
| Shares Outstanding | 57.0 million (basic, 2026 Q2) |
Abeona Therapeutics Income Statement
| FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | |
|---|---|---|---|---|---|---|
| Revenue | $10.0M | $3.0M | $1.4M | $3.5M | — | $5.8M |
| Cost of Goods Sold | — | — | — | — | — | $1.5M |
| Gross Profit | — | — | — | — | — | $4.3M |
| Operating Income | -$81.4M | -$89.8M | -$50.9M | -$47.1M | -$64.2M | -$89.4M |
| Pre-Tax Income | -$84.2M | -$84.9M | -$39.7M | -$54.2M | -$63.7M | $71.3M |
| Income Tax | — | — | — | — | — | $100,000 |
| Net Income | -$84.2M | -$84.9M | -$39.7M | -$54.2M | -$63.7M | $71.2M |
| Diluted EPS | -$22.75 | -$21.50 | — | -$2.53 | -$1.55 | $1.01 |
Abeona Therapeutics Quarterly Results
| 2025 Q3 | 2025 Q4 | 2026 Q1 | 2026 Q2 | |
|---|---|---|---|---|
| Revenue | — | — | $8.7M | $11.4M |
| Net Income | -$5.2M | -$20.5M | -$17.1M | -$20.2M |
| Diluted EPS | -$0.10 | -$0.31 | -$0.30 | -$0.35 |
Abeona Therapeutics Balance Sheet
| FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | |
|---|---|---|---|---|---|---|
| Cash & Equivalents | $12.6M | $32.9M | $14.2M | $14.5M | $23.4M | $78.4M |
| Current Assets | $97.7M | $55.4M | $53.1M | $55.7M | $100.9M | $204.9M |
| Total Assets | $151.2M | $79.6M | $64.2M | $64.0M | $108.9M | $219.6M |
| Current Liabilities | $42.0M | $16.6M | $7.8M | $13.4M | $16.6M | $29.6M |
| Total Long-Term Debt | $1.8M | — | — | — | $19.0M | $20.0M |
| Total Liabilities | $48.6M | $28.2M | $37.5M | $49.2M | $64.9M | $60.4M |
| Shareholders' Equity | $102.6M | $51.4M | $26.8M | $14.8M | $44.0M | $159.2M |
Abeona Therapeutics Cash Flow Statement
| FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | |
|---|---|---|---|---|---|---|
| Cash From Operations | -$35.0M | -$65.7M | -$43.5M | -$37.0M | -$56.0M | -$76.3M |
| Cash From Investing | -$83.7M | $66.1M | -$24.0M | $208,000 | -$39.2M | $105.0M |
| Cash From Financing | $1.9M | $24.9M | $43.2M | $37.1M | $104.1M | $26.0M |
| Free Cash Flow | -$36.4M | -$69.9M | -$43.6M | -$37.3M | -$58.5M | -$84.3M |
Figures from Abeona Therapeutics' 10-K and 10-Q filings with the SEC, as of 2026-10-14. Fiscal years follow the company's own reporting calendar. EPS and share counts are adjusted for later stock splits. See the full Abeona Therapeutics financials page for every line item.
Abeona Therapeutics Company Profile
| Ticker | ABEO |
|---|---|
| Exchange | Nasdaq |
| Industry | Pharmaceutical Preparations |
| Headquarters | Cleveland, Ohio |
| Incorporated in | Delaware |
| Fiscal Year End | December 31 |
| SEC Filer Category | Non-accelerated filer, smaller reporting company |
| SEC CIK | 0000318306 |
Frequently Asked Questions
What was Abeona Therapeutics' revenue in fiscal 2025?
Abeona Therapeutics (ABEO) reported revenue of $5.8M for fiscal 2025.
What is Abeona Therapeutics' annual revenue history?
Abeona Therapeutics' annual revenue by fiscal year: 2020: $10.0M; 2021: $3.0M; 2022: $1.4M; 2023: $3.5M; 2025: $5.8M.
What was Abeona Therapeutics' net income in fiscal 2025?
Abeona Therapeutics reported net income of $71.2M for fiscal 2025.
What was Abeona Therapeutics' earnings per share (EPS) in fiscal 2025?
Abeona Therapeutics' diluted EPS was $1.01 for fiscal 2025 (adjusted for any later stock splits).
How much free cash flow did Abeona Therapeutics generate in fiscal 2025?
Abeona Therapeutics generated -$84.3M of free cash flow in fiscal 2025.
What was Abeona Therapeutics' revenue last quarter?
In its most recent reported quarter (2026 Q2), Abeona Therapeutics reported revenue of $11.4M.
How much debt does Abeona Therapeutics have?
Abeona Therapeutics reported $20.0M of long-term debt, including the current portion, at the end of fiscal 2025.
How many shares of Abeona Therapeutics are outstanding?
Abeona Therapeutics reported a weighted average of 57.0 million basic shares outstanding in 2026 Q2.
What is Abeona Therapeutics' market cap?
Based on its latest closing price, Abeona Therapeutics (ABEO) has a market capitalization of about $257.9M.
When does Abeona Therapeutics' fiscal year end?
Abeona Therapeutics' fiscal year end, as registered with the SEC, is December 31.
Where is Abeona Therapeutics headquartered?
Abeona Therapeutics lists its business address in Cleveland, Ohio in its SEC filings.